Abstract
BackgroundPatients (pts) with RA have increased risk of myocardial infarction (MI) and stroke that cannot be completely explained by traditional cardiovascular (CV) risk factors. Tofacitinib is an oral JAK inhibitor...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have